By day 29 of the trial, 11.2% in the remdesivir group and 11.3% in the control group had an adverse cardiac event.
Study shows no link between remdesivir, cardiac events
Published in COVID-19
More from COVID-19More posts in COVID-19 »
- Very few US adults getting new flu, COVID, RSV vaccines, even in nursing homes
- US respiratory virus activity remains low ahead of holiday season
- Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
- Adults with migraines at higher risk of depression during pandemic, study shows